Case Studies

The limited sensitivity of the A1C test may result in missed or delayed diagnosis of Type 2 diabetes, whereas the use of current OGTT criteria will fail to identify a high proportion of individuals with A1C >6.5%. Further studies and discussion are needed before revising guidelines for Type 2 diabetes …

Studies of modifiable risk factors for stroke have been conducted largely in developed countries. Few data have been collected in the developing world, where 85% of stroke mortality occurs… 

A simple community program has been shown to be effective in preventing excess weight gain with a program based on simple health messages, small changes behavior, and delivered conveniently in a community setting…. 

Study shows visually impaired people can use insulin pens even though the labels on the popular insulin pen used by people with diabetes warn against visually-impaired people using pens to measure out and administer their insulin dosage….

It was not hypoglycemia from intensive control or intensive control itself that caused the increased deaths in the ACCORD study. This information will not be reported on every TV station as the original study results were, so it is your responsibility to inform your patients that intensive control that is …

Eli Lilly and Company, and Amylin announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with Type 2 diabetes.  

  Research suggests promising chemopreventive role for metformin by reducing the risk of pancreatic cancer by 62 percent.

  Near-normal control of glucose beginning as soon as possible after diagnosis would greatly improve the long-term prognosis of Type 1 diabetes, concludes a study published in the July 27, 2009, issue of the Archives of Internal Medicine, which updates information about the clinical course of Type 1 diabetes.

Scores comparable to standard therapy on heart attacks, strokes and CV death but doubled incidence of heart failure warrants monitoring by physician.

ROADMAP is the first-ever, large-scale clinical trial, being conducted in 19 European countries to evaluate whether the angiotensin II receptor blocker (ARB) olmesartan medoxomil can prevent the onset of microalbuminuria in patients with Type 2 diabetes (T2DM).